Microbot Medical Gets FDA Approval For Pivotal Human Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical has received FDA approval for a pivotal human clinical trial in the U.S. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers. Concurrently, it is completing biocompatibility tests required by its IDE application.
June 03, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical has received FDA approval for a pivotal human clinical trial in the U.S. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers. Concurrently, it is completing biocompatibility tests required by its IDE application.
FDA approval for a pivotal human clinical trial is a significant milestone for Microbot Medical. This approval, along with the agreement with a leading academic medical center, is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100